Zhejiang Hisun Pharmaceutical Co., Ltd.

Zhenliang Chen

Hua Bai

Ravindra Kumar Pandey

Xiaohe Zheng

Xiaoyu Liu

Fei Zheng

Yihui Chen

Nayan Patel

Manivannan Ethirajan

Tianmin Zhu

Yumei Wu

Chunhua Jin

Shoufeng Ming

A targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof is provided, which improves the selectivity of photosensitizers to tumor cells, has better tolerance, can reach maximum blood concentration in 24 hours, has a bigger conjugated system, a longer absorption wavelength and an advantage in treating depth tumors; the wavelength area does not need to consume much energy of a light-output device and even LEDs can be used, which render PDT more practical and economical. The targeting thymidine kinase photosensitizer can be used for diagnosis and for treating prostatic carcinoma via the guidance of fluorescence imaging. The pharmaceutical composition uses a combination of a chemotherapeutic agent and the targeting thymidine kinase photosensitizer, which further improves the therapeutic effect of the PDT method, expands the application range for tumors and has good effects on metastatic tumors as well.

Targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof

Disclosed are a cyanine dye compound and a preparation method therefor, and a dual-function agent for photodynamic therapy and a preparation method therefor. The provided cyanine dye compound is connected to multiple markers, which improves the accuracy of combination of dye and tumor cells, effectively reduces the background value, and avoids excessive residues in the liver. The provided cyanine dye compound is conjugated with the photosensitizer at 2'&#x2033; position, so that tumor highly absorbs the conjugates.

Cyanine dye compound and preparation method therefor, and dual-function agent for photodynamic therapy and preparation method therefor

The present invention provides a crystalline form of HPPH (2-((1'-n-hexyloxy)ethyl)-2-divinyl-pyropheophorbide-a): The crystalline form can be characterized by an X-ray powder diffraction (XRD) pattern and differential scanning calorimeter (DSC) pattern. The present invention also provides a method for preparing the crystalline form of HPPH.

Crystalline form of 2-((1'-n-hexyloxy) ethyl)-2-divinyl-pyropheophorbide-a and method for preparing thereof

The present invention provides a novel compound of formula I, which has an agitation effect on the peroxisome proliferator-activated receptor subtype &#x3b4; (PPAR&#x3b4;), to a pharmaceutical composition comprising the compound, to a process for preparation of the compound and to use of the compound in the manufacture of a medicament for treating or preventing a disease which could be treated or prevented by activating PPAR&#x3b4; thereof, said disease is one or more from the group comprising metabolic syndrome, obesity, dyslipidemia, pathoglycemia, insulin resistance, senile dementia and tumors. The present invention also relates to a new intermediate used in the preparation of the novel compound and a process for preparation of the intermediate. 

Compound with agitation effect on peroxisome proliferator-activated receptor process for its preparation and use thereof

Growing community of inventors

Taizhou, China

Zhenliang Chen